A B S T R A C T Agents known to interact with either microtubules or microfilaments influenced the antigen-induced release of histamine from the leukocytes of allergic individuals. Deuterium oxide (D20) which stabilizes microtubules and thereby favors their formation enhanced histamine release markedly. Concentrations as low as 5% increased antigen-induced release somnewhat while concentrations as high as 75% had no effect on release in the absence of antigen. Enhancement occurred over a wide range of antigen concentrations and was also seen when release was initiated by antibody to IgE or IgG. When the release process was divided into two stages a D20 activity could be demonstrated only in the second stage. However, when D20 was present in the first stage together with agents which raise cyclic AMP levels and thereby inhibit release it partially reversed this inhibition. Colchicine, demecolcine, and vinblastine, compounds known to disaggregate microtubules, i.e., have an effect opposite to that of D20, inhibited the release of histamine and counteracted the effects of D20. The inhibitory action of colchicine was greater if cells were treated with colchicine before rather than after activation with antigen. Cytochalasin B, a compound which causes the disappearance of microfilaments, had variable effects on histamine release. The most frequently seen response was slight enhancement. Neither D20 nor cytochalasin B altered cyclic AMP levels in leukocytes. These observations support and strengthen the view that an intact and functioning microtubule system is directly important for the secretion of histamine from leukocytes and suggest that microfilaments might have multiple indirect effects.
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INTRODUCTION
Antigen-mediated release of histamine from the leukocytes of allergic individuals is a good in vitro model for allergic reactions. The extent of release correlates well with clinical symptoms (1) and drugs, e.g., isoproterenol and theophylline, which alleviate the in vivo symptoms also inhibit the in vitro release process (2) . At the same time the mechanism by which histamine is released from leukocytes is fundamentally similar to the release process in other tissues, with cell-bound antibody (IgE) acting as a receptor and antigen replacing a hormone or other releasing agent.
Colchicine, a drug known to disrupt microtubules, has been shown to inhibit the release of a variety of compounds (3-6) including histamine from leukocytes (7).
This observation has been interpreted in all cases as indicating that microtubules play a role in the release process. Deuterium oxide (D20) which is known to stabilize microtubules (8, 9) , i.e., act in a manner opposite to colchicine, has been studied in three release systems. In the rat peritoneal mast cell it potentiates the release of histamine by other releasing agents and also acts as a releasing agent itself (3); in the cat adrenal gland it potentiates the release of catecholamines by acetylcholine (6) ; and in the thyroid gland it inhibits release (10).
Recently cytochalasin B, a drug which causes the disappearance of 40-70 A microfilaments from cells but has no effect on the morphology of microtubules (11, 12) has been shown to inhibit the release of thyroid hormone and growth hormone (13, 14) and potentiate the release of insulin (15) .
The present study was designed to evaluate the role of microtubules and microfilaments in the release of histamine from leukocytes through the use of D20, colchicine, and cytochalasin B individually and in combination.
It was found that D20 potentiated the release process markedly while colchicine and other microtubule dis-rupters inhibited release and counteracted the effect of D20. Cytochalasin B had variable effects depending on the individual cells used and the level of histamine release obtained. In the majority of cases it potentiated release somewhat although inhibition was occasionally observed. These results support the view that microtubules are directly important in the release process and suggest that microfilaments have multiple indirect effects. METHODS Leukocytes from allergic individuals were prepared by dextran sedimentation as previously described (16). They were resuspended at a dilution of approximately 107 cells/ml and incubated at 37'C in a medium consisting of (mM): NaCl, 120; KCl, 5; CaCl2, 0.6; MgC12, 1; tris (hydroxymethyl) aminomethane, 25; human serum albumin, 0.1%, adjusted to pH 7.4. D20 replaced H20 in the medium as required. Experiments involving colchicine were also carried out using a phosphate buffer since tris has been reported to interfere with the action of colchicine (17) . Under our conditions the effect of colchicine in the two buffers was the same. In experiments designed to study the two stages of the release process (18) cells were exposed to antigen for 2 min in medium free of calcium and magnesium, washed twice and resuspended in the absence of antigen in the complete medium described above. Histamine released from the cells into the supernatant fluid was measured by a micromodification of the fluorometric technique of Shore (19, 20) . All experiments were carried out in duplicate and repeated using the cells of at least two and usually three to five different individuals. The average difference between duplicate measurements using this technique was less than 5%. protein prepared from bovine adrenal cortex. Charcoal is used to separate free and bound nucleotide.
Ragweed antigen E was provided by Dr. T. P. King (22) and rye grass group I antigen by Dr. D. G. Marsh (23) . D20 was obtained from BioRad Laboratories (Richmond, Calif.), demecolcine (Colcemid) from Ciba Pharmaceutical Co. (Summit, N. J.), vinblastine sulfate (Velban) from Eli Lilly & Co. (Indianapolis, Ind.), and cytochalasin B from Imperial Chemical Industries (Alderly Park, England). This last drug was dissolved in dimethylsulfoxide (DMSO) (10 mg/ml) and diluted as required with incubation medium. DMSO controls were included in all experiments involving cytochalasin B.
RESULTS
Effects of DAO on histamine release. D20 markedly enhanced the release of histamine from leukocytes under a variety of experimental conditions. D20 at levels as low at 5% significantly increased release due to antigen while concentrations as high as 75% had no effect in the absence of antigen (Fig. 1) . Enhancement occurred over a wide range of antigen concentrations including levels insufficient to cause release alone and levels high enough to inhibit the process (Fig. 2) . Enhancement of anti-IgE mediated release (24) was similar in all respects to that noted with antigen ( Fig. 2) . Potentiation of release by D20 was also seen using the cells of individuals who can maximally release only 10-20% of their total histamine and in situations where the releasing agent usually can induce only a limited response, i.e., antibodies to IgG (25) (Fig. 3) . When the time course of release was studied, D20 increased the rate of release rather than otherwise altering the time course (results not shown). Enhancement of histamine'release by D20 of the order of magnitude illustrated in Figs. 1-3 was seen in experiments with the cells of all individuals studied (Table I ). The per cent enhancement is, of course, related to control release in that if release in the absence of D20 is 50% enhancement cannot exceed 100% while if control release is 5% enhancement can be 2000%.
The release of histamine from leukocytes can be operationally divided into two stages, an antigen-dependent, calcium-independent first stage and an antigen-independent, calcium-dependent second stage (18) . The effects of D20 on the two stages of the release reaction were studied by carrying out either the first or the second incubation in medium containing D20. Enhancement occurred only when D20 was present during the second stage (Table II) .
Interaction between DAO and colchicine, dernecolcine, or vinblastine. Since the effects of D20 on histamine release are presumably due to its action on microtubules, drugs such as colchicine, demecolcine (Colemid), and vinblastine which disaggregate microtubules should counteract the enhancement of release caused by D20. To study this interaction cells were incubated with or without colchicine, demecolcine, or vinblastine for 20 min at 40C., washed and resuspended with antigen in either normal medium or medium in which a portion of the H20 was replaced by D20. Colchicine, as reported previously (7) inhibited histamine release; inhibition was also observed after treatment of the cells with demecolcine or vinblastine (Fig. 4) . In the presence of both D20 and (Fig. 4) . Similar results were obtained in four separate experiments involving D20 and colchicine and in two experiments with D20 and demecolcine or vinblastine. Interaction between D.O and isoproterenol or prostaglandin Em. Compounds that raise cyclic AMP levels in leukocytes, e.g., isoproterenol and prostaglandins Ei and E2, are known to inhibit histamine release through an action confined largely if not completely to the first stage of the process (26) . In contrast D20 acts only in the second stage (Table II) . The interraction between D20 and cyclic AMP was studied in two different sets of experiments. In the first set either isoproterenol or prostaglandin E2 was present during the first incubation with (Table IV) .
Effects of cytochalasin B on histamine release. The
effects of cytochalasin B on histamine release from the cells of several individuals were examined (Table V) . The results varied considerably ranging from inhibition rostaglandin E2-in two cases to moderate enhancement of release in ,2 (1.4 X 10WM) others. Cytochalasin B (5 tAg/ml) had no effect on re-;Ynesium, washed 'dium containing lease in the absence of antigen. It also had no effect on cyclic AMP levels in leukocytes after incubation for 2944 E. Gillespie and L. M. Lichtenstein Fig. 6 . The drug appears to decrease the initial time lag seen before release begins and also increase the rate of release slightly. DMSO at a level equal to that in the cytochalasin solution (0.05%) had no effect on the release process. DISCUSSION The present study explores the effects of compounds known to interact with microtubules or microfilaments on the antigen-induced release of histamine from human leukocytes. The results obtained considerably strengthen the view of Levy and Carlton (7) that microtubules are involved in this process. These investigators found that colchicine, a drug which acts by binding to the subunits of microtubules and thereby leading to their disaggregation (27-29) inhibited histamine release. This action of colchicine was considerably enhanced by cold which is known to cause the reversible breakdown of microtubules into subunits (30, 31) . In the present study we have found that two other drugs, demecolcine and vinblastine, which disrupt microtubules (32, 33) also inhibit the release of histamine from leukocytes. At the same time D20 which is known to favor the formation of microtubules in other cells (8, 9) markedly potentiates antigeninduced histamine release. The enhancement of release caused by D20 is greater by far than that seen with any other agent reported to date. The effects of D20, unlike those of colchicine, were found to be rapid in onset and readily reversed by removing the D20. This made it possible to determine at what stage in the release reaction a functioning microtubule system is required. When the release reaction was divided into two stages D20 acted only in the second stage of the process suggesting that microtubules are necessary for the actual secretion of histamine rather than for the initial antigen-induced activation of the process. This finding fits well with the idea of others (3, 6, 7) that the microtubule system is involved in some way with the movement of granules toward the cell membrane. The interaction seen between D20 and isoproterenol or prostaglandin E2 is of particular interest. These latter two compounds inhibit the release of histamine presumably by raising cyclic AMP levels through an action in the first (activation) stage of the release process (26) . D20, when also present in the first stage, can partially prevent this inhibition. This result has important implications. First since D20 alters an event taking place Histamine Release-Effects of D2O, Colchicine, and Cytochalasin B 294.5 in the first stage of the release reaction it suggests that this stage includes a change in the state of the microtubule system. Second it supports the idea that cyclic AMP inhibits release through an action on the xnicrotubule system. Cyclic AMP has been shown to alter the equilibrium between formed microtubules and their subunits in tissue slice preparations (34) . In the absence of calcium, the nucleotide promoted the disaggregation of microtubules into subunits, i.e. had an effect opposite to that of D20. The present finding that D20 partially prevents the inhibition of release by cyclic AMP is consistent with these findings.
The observation that colchicine is a less effective inhibitor of release when the cells are exposed to antigen before rather than after colchicine treatment provides additional strong evidence that the first stage of the release process involves a change in the state of the microtubule system. The change appears to be in the direction of greater microtubule stability since it leads to increased resistance to cold and/or colchicine.
The effects of cytochalasin B on the release of histamine are of interest. This drug, a metabolite of the mold, Helninthosporiwn dematoideum, has been shown to cause the disappearance of 40-70 A microfilaxnents but has no apparent effect on microtubules in several cell types (11, 12) . Its potential effects on metabolism have not been studied in any detail. Cytochalasin B inhibits several processes not known to involve microtubules, e.g. cytokinesis (11) , cell motility (35, 36) , the ingestion step in phagocytosis (36, 37) , axonal elongation (38) , and the dispersal of melanin granules in frog melanocytes (39, 40) . At the same time it inhibits the release of thyroid hormone (13) , growth hormone (14) and histamine from mast cells (41) but potentiates the release of insulin (15) . The effects of cytochalasin B on histamine release observed in the present study were variable. The most frequently seen effect was enhancement of release although with the cells of two out of eight individuals significant inhibition of release was observed. These results can best be explained by either assuming that cytochalasin B has two or more independent actions or that its on known action, i.e. disruption of microfilaments can have two or more effects on the release process. The occurrence of microfilaments in basophils does not appear to have been described. In other cell types however microfilaments are frequently found in close association with the cell membrane (12, 42) . If this is also the case in basophils loss of these microfilaments could well alter the configuration of the membrane which, in turn, could influence both the movement of compounds across the membrane and also the interaction between releasing agents and membrane receptors. The present results with cytochalasin B are most easily interpreted in this last framework.
